A real-world retrospective study to determine the safety and effectiveness of naftifine 2% cream in the treatment of Tinea cruris and Tinea corporis in Indian patients
DOI:
https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20250429Keywords:
Naftifine, Tinea infections, Tinea corporis, Tinea cruris, Superficial fungal infections, DermatophytosisAbstract
Background: This real-world retrospective analysis of the case record forms (CRFs) was done to evaluate the safety, effectiveness, compliance, and tolerability of naftifine 2% cream in treating superficial infections, especially Tinea corporis and Tinea cruris, in Indian patients.
Methods: The data was collected from 158 dermatologists/physicians’ outpatient department in India, on using naftifine 2% cream in patients presenting with new or recurrent Tinea infections. The CRFs of 1258 patients who had previously visited the dermatology outpatient department from July 2023 to May 2024 and received naftifine 2% cream as monotherapy or in combination therapy at the discretion of the treating physician were included in the study.
Results: A total of 1,258 eligible CRFs were analyzed, revealing that 81% of patients treated with naftifine 2% cream achieved clinical cure, while 99.6% achieved mycological cure. Adverse events were reported in only 2.6% (n=33) of patients, and naftifine 2% cream treatment was well tolerated.
Conclusions: This retrospective study suggests that naftifine 2% cream is safe and effective in patients with superficial fungal infections, including Tinea corporis and Tinea cruris.
Metrics
References
Jerajani H, Janaki C, Kumar S, Phiske M. Comparative assessment of the efficacy and safety of sertaconazole (2%) cream versus terbinafine cream (1%) versus luliconazole (1%) cream in patients with dermatophytoses: A pilot study. Indian J Dermatol. 2013;58(1):34. DOI: https://doi.org/10.4103/0019-5154.105284
Jassim Mohammad M, Musa H, Khalaf M. Epidemiological study of dermatophytes spread in Anbar Governorate. Int Tinnitus J. 2024;1:80-6.
Sahni K, Singh S, Dogra S. Newer Topical Treatments in Skin and Nail Dermatophyte Infections. Indian Dermatol Online J. 2018;9(3):149-58. DOI: https://doi.org/10.4103/idoj.IDOJ_281_17
Rotta I, Ziegelmann PK, Otuki MF, Riveros BS, Bernardo NLMC, Correr CJ. Efficacy of Topical Antifungals in the Treatment of Dermatophytosis. JAMA Dermatol. 2013;149(3):341. DOI: https://doi.org/10.1001/jamadermatol.2013.1721
Banerjee M, Ghosh AK, Basak S, Das KD, Gangopadhyay DN. Comparative evaluation of effectivity and safety of topical amorolfine and clotrimazole in the treatment of tinea corporis. Indian J Dermatol. 2011;56(6):657-62. DOI: https://doi.org/10.4103/0019-5154.91823
Thompson AJ, Tyring SK. Naftifine HCl 2% Cream for the Treatment of Tinea Pedis: A Review. Curr Dermatol Rep. 2013;2(3):191-3. DOI: https://doi.org/10.1007/s13671-013-0049-7
Gupta AK, Ryder JE, Cooper EA. Naftifine: A review. J Cutan Med Surg. 2008;12(2):51-8. DOI: https://doi.org/10.2310/7750.2008.06009
Gusliakova O, Verkhovskii R, Abalymov A, Lengert E, Kozlova A, Atkin V, et al. Transdermal platform for the delivery of the antifungal drug naftifine hydrochloride based on porous vaterite particles. Mater Sci Eng C Mater Biol Appl. 2021;119:111428. DOI: https://doi.org/10.1016/j.msec.2020.111428
Plaum S, Verma A, Fleischer AB Jr, Olayinka B, Hardas B. Detection and relevance of naftifine hydrochloride in the stratum corneum up to four weeks following the last application of naftifine cream and gel, 2%. J Drugs Dermatol. 2013;12(9):1004-8.
Kyle AA, Dahl M V. Topical Therapy for Fungal Infections. Am J Clin Dermatol. 2004;5(6):443-51. DOI: https://doi.org/10.2165/00128071-200405060-00009
Sinha SD, Rajamma A, Bandi MR, Sriramadasu SC, Sahu S, Kothiwala RK, et al. Efficacy and Safety of Naftifine Hydrochloride 2% Gel in Interdigital Tinea Pedis: A Phase III Randomised, Double-Blind, Parallel-Group, Active-Controlled Study in Indian Adult Patients. Clin Drug Investig. 2023;43(7):565-74. DOI: https://doi.org/10.1007/s40261-023-01288-1
Patro N, Suryatale PR, Pandya I, Mian NZ, Chinda M, Daultani PM, et al. A phase III randomized controlled clinical trial evaluating the efficacy and safety of naftifine 2% cream versus terbinafine 1% cream in patients with superficial fungal infection of the skin. Int J Res Dermatol. 2024;10(4):170-6. DOI: https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20241599
Godse K, Vidya TS, Adhikari P, Prasad AK, Raj C, Bhaskar G, et al. A real-world observational study to evaluate the safety & effectiveness of Naftifine 2% cream in patients with superficial fungal skin infection. IP Indian J Clin Exp Dermatol. 2024;10(3):260-5. DOI: https://doi.org/10.18231/j.ijced.2024.046
Parish LC, Parish JL, Routh HB, Fleischer AB Jr, Avakian EV, Plaum S, et al. A randomized, double-blind, vehicle-controlled efficacy and safety study of naftifine 2% cream in the treatment of tinea pedis. J Drugs Dermatol. 2011;10(11):1282-8.
Millikan LE, Galen WK, Gewirtzman GB, Horwitz SN, Landow RK, Nesbitt LT Jr, et al. Naftifine cream 1% versus econazole cream 1% in the treatment of tinea cruris and tinea corporis. J Am Acad Dermatol. 1988;18(1 Pt 1):52-6. DOI: https://doi.org/10.1016/S0190-9622(88)70008-0
Trailokya AA, Shirsat AB, Madhu R, Shah B. Naftifine: A Topical Allylamine for Superficial Dermatophytosis. J Assoc Physicians India. 2023;71(5):80-5. DOI: https://doi.org/10.5005/japi-11001-0241
Downloads
Published
How to Cite
Issue
Section
